We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diabetic Blood Tests Affected by Elevated Liver Enzymes

By LabMedica International staff writers
Posted on 28 Jun 2012
Print article
Diabetes is currently diagnosed using venous fasting plasma glucose or an oral glucose tolerance test, although some authorities are recommending the HbA1c blood test as an alternative.

Measurement of glycated hemoglobin (HbA1c) has several advantages over glucose, but there are also potential disadvantages, with falsely low results in patients with increased liver enzyme concentrations in general, but also in severe liver disease and liver failure.

Clinical biochemists at the Odense University Hospital (Denmark) investigated the correlation between HbA1c and venous fasting plasma glucose. For comparison, a large cohort of 10,065 patients with different degrees of increased plasma liver enzyme measurements was compared with a control group with normal liver function. The mean age of both male and female patients was 57 years.

Analysis of alanine aminotransferase (ALT), gamma glutamine transferase (GGT) and glucose were performed in a Modular System (Roche Diagnostics; Basel, Switzerland) with dedicated reagents. HbA1c was measured by high-performance liquid chromatography as fraction of total hemoglobin using either a Tosoh G5 or G7 analyzer (Medinor; Broendby, Denmark). Correlations were investigated in four patient groups divided according to their liver enzyme concentrations.

The correlation between HbA1c and plasma glucose was high in all groups, which was confirmed with multiple regression analysis. The interaction analysis revealed that linear regression lines were significantly different for men and women, with increase of both liver enzyme measurements and also for women, with increased ALT. Of note, GGT also remained significantly associated with HbA1c while ALT did not correlate significantly with HbA1c in this model. When compared with biological variation for HbA1c, only men with increased measurements of both liver enzymes had a clinically important decrease in HbA1c.

The authors concluded that the study strongly indicates that increased liver enzyme concentrations in general do not bias the correlation between glycated hemoglobin and fasting plasma glucose. However, men with increased concentrations of both liver enzymes do have a slightly decreased HbA1c, and, if the clinical suspicion is strong enough, one should consider supplementary testing. Of note, patients with distinct liver failure and/or pronounced hemolysis were not evaluated in this study and HbA1c results should therefore be interpreted with caution in such patients. The study was published on May 16, 2012, in the journal Diabetic Medicine.

Related Links:

Odense University Hospital
Roche Diagnostics
Medinor


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.